Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Cancer
    • Addition of diabetes...

    Addition of diabetes drug Metformin improves survival in lung cancer patients: JAMA Oncology

    Written by Medha Baranwal Baranwal Published On 2019-09-20T19:10:00+05:30  |  Updated On 11 Aug 2021 5:31 PM IST

    Mexico: The diabetes drug metformin apart from lowering blood sugar in type 2 diabetes patients has been previously shown to have varied benefit in other health conditions as well. Now, a recent study has shown benefit of the drug for lung cancer patients.


    According to results of the phase 3 study, published in the JAMA Oncology journal, the addition of metformin in patients with EGFR (epidermal growth factor receptor)-mutated lung adenocarcinoma increased progression-free and overall survival sans any significant increase in adverse events.


    Metformin hydrochloride is emerging as a repurpose anticancer drug. The drug has shown to improve outcomes across a wide variety of neoplasms, including lung cancer in preclinical and retrospective studies.


    Oscar Arrieta, Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico, and colleagues assessed the progression-free survival in patients with advanced lung adenocarcinoma who received EGFR–TKIs (tyrosine kinase inhibitors) therapy plus metformin compared to those who received EGFR-TKIs alone.


    In the study, 139 patients (Mean age: 59.4 and 65.5% were female) were randomized to receive standard EGFR-TKIs (n=70) or EGFR-TKIs plus metformin 500 mg twice daily (n=69) from March 2016 to December 2017.


    All the participants had histologically confirmed stage IIIb/IV lung adenocarcinoma with an activating EGFR mutation and measurable lesions. All were naïve to EGFR-TKIs, had an Eastern Cooperative Oncology Group performance status of 2 or less, and a life expectancy of at least 12 weeks. Median follow-up was 16.9 months.


    Also Read: Metformin prevents endometriosis in breast cancer patients

    Key findings include:

    • The median PFS was significantly longer in the EGFR-TKIs plus metformin group compared with the EGFR-TKIs group (13.1 months compared with 9.9 months).

    • The median overall survival was also significantly longer for patients receiving combination therapy: 31.7 months vs 17.5 months.

    • Patients allocated to receive added metformin were more likely to respond to EGFR-TKI therapy: 71.0% vs 54.3%.

    • The combination lowered the risk of non-response, achieving an objective response rate of 0.48.

    • The addition of metformin was the only factor independently associated with better overall survival, decreasing the risk of death by half.

    • Grade 3/4 adverse events in both arms were similar in frequency in both arms and included diarrhoea, rash, nausea, and mucositis.


    Also Read: Diabetes drug Metformin may promote brain repair after stroke in females


    "To our knowledge, this is the first study to prospectively show that the addition of metformin to standard EGFR-TKIs therapy in patients with advanced lung adenocarcinoma significantly improves PFS. These results justify the design of phase 3, placebo-controlled study," wrote the authors.


    To read the complete study log on to doi:10.1001/jamaoncol.2019.2553
    cancerdiabetes drugEGFRepidermal growth factor receptorlung adenocarcinomaLung CancerMedical newsmetforminOscar Arrietaprogression free survivalrecent medical newssurvivalTKIstyrosine kinase inhibitors

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medha Baranwal Baranwal
    Medha Baranwal Baranwal
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok